Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. (Q51051365)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Saye Khoo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Marco Siccardi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Alessandro Schipani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

David Back

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Gerry Davies

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

17 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

107-116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095

17 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Switching from efavirenz to nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Optimal antiviral switching to minimize resistance risk in HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

The Simcyp population-based ADME simulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Maraviroc: in vitro assessment of drug-drug interaction potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Pharmacokinetics of the treatment switch from efavirenz to nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Pharmacokinetics of nevirapine: initial single-rising-dose study in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0184-8

Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.

21 January 2018

1 reference

12 December 2020

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

1 reference

12 December 2020

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450

1 reference

12 December 2020

Efavirenz--still first-line king?

1 reference

12 December 2020

Maraviroc: pharmacokinetics and drug interactions

1 reference

12 December 2020

10.1007/S40262-014-0184-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25245943%20AND%20SRC:MED&resulttype=core&format=json

release_can5mhrn6vgozmkrovkvpejyuy

17 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/can5mhrn6vgozmkrovkvpejyuy

24 November 2022

mapped directly with Wikidata item

1 reference